Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has filed a patent application to protect the recently developed Optimer binder sequences for novel applications in fast moving consumer goods generated as part of its partnership with Unilever.
Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease
Researchers developed an RNA-based switch, the pA regulator system, to control gene expression in mammalian cells by modulating synthetic polyA signal cleavage, offering a novel approach for gene therapy applications.